Acknowledgements
PMF
MARION, VIRUS
This study was supported through the UK Vaccines Network by the UK Department of Health and Social Care (projects 16/107/02 and 16/107/03). The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care. GMW was supported by an Oak foundation fellowship and a Wellcome Trust grant (203077_Z_16_Z). The authors are grateful for the skilled input of the following individuals from the University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine: Nicholas Byard, Hannah Preston-Jones, Syona Neeraj, Nicola Greenwood, Merin Thomas, Celia Mitton, Dina Pena Suarez, Megan Baker, Marion Watson, Jack Quaddy, and Oliver Conway. We also thank Brian Angus for acting as our local safety monitor. We thank Jeroen Kortekaas and Paul Wichgers Schreur at Wageningen Bioveterinary Research, Netherlands for providing the RVFV-4s_eGFP virus used for neutralising antibody assays. GMW, SCG, BC and AVSH are Jenner Investigators.
Methodology: PMF, AVSH, GMW, DJ, DW, AL; Validation: JNG, HKK, DM, DW; Formal analysis: DW, DJ; Investigation: DJ, PMF, AP, IP, DW, JNG, HKK, DM; Resources: KJE; Data Curation: DJ, DW, CT; Writing - Original Draft: DJ, DW, GMW; Writing - Review & Editing: All authors contributed to the reviewing and editing of the report and approved the final version; Visualization: DJ, DW; Supervision: TAB, SCG, GMW; Project administration: AL, AB, NT; Funding acquisition: GMW, AVSH, BC, PK; All data in the manuscript was accessed and verified by DW and DJ.
PMF reports funding from the Brazilian Government (CAPES) for PhD work and consulting fees from Vaccitech, a company developing ChAdOx1 vectored vaccines; KJE is a named contributor to a patent relating to ChAdOx1 MERS; TAB reports grant funding from the Medical Research Council UK; SCG is named as an inventor on the patent covering ChAdOx1 use as a vaccine vector and holds stock in Vaccitech; AVSH has recieved royalties from the COVID-19 vectored ChAdOx1 vaccine to both his institution and self, and is named as an inventor on the patent covering ChAdOx1 use as a vaccine vector; DJ, DW, AP, IP, AL, NT, AB, CT, JNG, HKK, DM, BC, PK, and GMW declare no interests.